Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation

Kenji Tago, Megumi Funakoshi-Tago, Satoshi Ohta, Hirotoshi Kawata, Hiroshi Saitoh, Hisanaga Horie, Chihiro Aoki-Ohmura, Junji Yamauchi, Akira Tanaka, Jitsuhiro Matsugi, Ken Yanagisawa

Research output: Contribution to journalArticle

Abstract

It is well established that nuclear factor κB (NF-κB) acts as one of the most important transcription factors for tumor initiation and progression, as it both protects cells from apoptotic/necrotic signals and accelerates angiogenesis and tumor metastasis, which is mediated via the expression of target genes. However, it has not yet been clarified how oncogenic signals accelerate the activation of NF-κB. In the current study, we utilized untransformed NIH-3T3 cells stably harboring a κB-driven luciferase gene to show that an oncogenic mutant of Ras GTPase augmented TNFα-induced NF-κB activation. Notably, enforced expression of cyclin-dependent kinase inhibitors, such as p27Kip1 and p21Cip1, effectively canceled the accelerated activation of NF-κB, suggesting that oncogenic Ras-induced cell cycle progression is essential for the hyperactivation of NF-κB. Furthermore, we found that Ras (G12V) augmented the transcriptional activation of NF-κB, and this activation required the p38 MAP kinase. We observed that a downstream kinase of p38 MAP kinase, MSK1, was activated by Ras (G12V) and catalyzed the phosphorylation of p65/RelA at Ser-276, which is critical for its transcriptional activation. Significantly, phosphorylation of the p65/RelA subunit at Ser-276 was elevated in patient samples of colorectal cancer harboring oncogenic mutations of the K-Ras gene, and the expression levels of NF-κB target genes were drastically enhanced in several cancer tissues. These observations strongly suggest that oncogenic signal-induced acceleration of NF-κB activation is caused by activation of the p38 MAP kinase–MSK1 signaling axis and by cell cycle progression in cancer cells.

Original languageEnglish
Pages (from-to)2493-2510
Number of pages18
JournalMolecular Oncology
Volume13
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Transcriptional Activation
p38 Mitogen-Activated Protein Kinases
Neoplasms
Cell Cycle
Phosphorylation
Gene Expression
ras Proteins
NIH 3T3 Cells
ras Genes
Cyclin-Dependent Kinases
Mitogen-Activated Protein Kinase Kinases
Luciferases
Genes
Colorectal Neoplasms
Transcription Factors
Neoplasm Metastasis
Mutation

Keywords

  • colorectal cancer
  • MSK1/2
  • NF-κB
  • p65/RelA
  • Ras

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. / Tago, Kenji; Funakoshi-Tago, Megumi; Ohta, Satoshi; Kawata, Hirotoshi; Saitoh, Hiroshi; Horie, Hisanaga; Aoki-Ohmura, Chihiro; Yamauchi, Junji; Tanaka, Akira; Matsugi, Jitsuhiro; Yanagisawa, Ken.

In: Molecular Oncology, Vol. 13, No. 11, 01.11.2019, p. 2493-2510.

Research output: Contribution to journalArticle

Tago, K, Funakoshi-Tago, M, Ohta, S, Kawata, H, Saitoh, H, Horie, H, Aoki-Ohmura, C, Yamauchi, J, Tanaka, A, Matsugi, J & Yanagisawa, K 2019, 'Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation', Molecular Oncology, vol. 13, no. 11, pp. 2493-2510. https://doi.org/10.1002/1878-0261.12580
Tago, Kenji ; Funakoshi-Tago, Megumi ; Ohta, Satoshi ; Kawata, Hirotoshi ; Saitoh, Hiroshi ; Horie, Hisanaga ; Aoki-Ohmura, Chihiro ; Yamauchi, Junji ; Tanaka, Akira ; Matsugi, Jitsuhiro ; Yanagisawa, Ken. / Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. In: Molecular Oncology. 2019 ; Vol. 13, No. 11. pp. 2493-2510.
@article{893f428397284f039c7382dc53d7ed6f,
title = "Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation",
abstract = "It is well established that nuclear factor κB (NF-κB) acts as one of the most important transcription factors for tumor initiation and progression, as it both protects cells from apoptotic/necrotic signals and accelerates angiogenesis and tumor metastasis, which is mediated via the expression of target genes. However, it has not yet been clarified how oncogenic signals accelerate the activation of NF-κB. In the current study, we utilized untransformed NIH-3T3 cells stably harboring a κB-driven luciferase gene to show that an oncogenic mutant of Ras GTPase augmented TNFα-induced NF-κB activation. Notably, enforced expression of cyclin-dependent kinase inhibitors, such as p27Kip1 and p21Cip1, effectively canceled the accelerated activation of NF-κB, suggesting that oncogenic Ras-induced cell cycle progression is essential for the hyperactivation of NF-κB. Furthermore, we found that Ras (G12V) augmented the transcriptional activation of NF-κB, and this activation required the p38 MAP kinase. We observed that a downstream kinase of p38 MAP kinase, MSK1, was activated by Ras (G12V) and catalyzed the phosphorylation of p65/RelA at Ser-276, which is critical for its transcriptional activation. Significantly, phosphorylation of the p65/RelA subunit at Ser-276 was elevated in patient samples of colorectal cancer harboring oncogenic mutations of the K-Ras gene, and the expression levels of NF-κB target genes were drastically enhanced in several cancer tissues. These observations strongly suggest that oncogenic signal-induced acceleration of NF-κB activation is caused by activation of the p38 MAP kinase–MSK1 signaling axis and by cell cycle progression in cancer cells.",
keywords = "colorectal cancer, MSK1/2, NF-κB, p65/RelA, Ras",
author = "Kenji Tago and Megumi Funakoshi-Tago and Satoshi Ohta and Hirotoshi Kawata and Hiroshi Saitoh and Hisanaga Horie and Chihiro Aoki-Ohmura and Junji Yamauchi and Akira Tanaka and Jitsuhiro Matsugi and Ken Yanagisawa",
year = "2019",
month = "11",
day = "1",
doi = "10.1002/1878-0261.12580",
language = "English",
volume = "13",
pages = "2493--2510",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation

AU - Tago, Kenji

AU - Funakoshi-Tago, Megumi

AU - Ohta, Satoshi

AU - Kawata, Hirotoshi

AU - Saitoh, Hiroshi

AU - Horie, Hisanaga

AU - Aoki-Ohmura, Chihiro

AU - Yamauchi, Junji

AU - Tanaka, Akira

AU - Matsugi, Jitsuhiro

AU - Yanagisawa, Ken

PY - 2019/11/1

Y1 - 2019/11/1

N2 - It is well established that nuclear factor κB (NF-κB) acts as one of the most important transcription factors for tumor initiation and progression, as it both protects cells from apoptotic/necrotic signals and accelerates angiogenesis and tumor metastasis, which is mediated via the expression of target genes. However, it has not yet been clarified how oncogenic signals accelerate the activation of NF-κB. In the current study, we utilized untransformed NIH-3T3 cells stably harboring a κB-driven luciferase gene to show that an oncogenic mutant of Ras GTPase augmented TNFα-induced NF-κB activation. Notably, enforced expression of cyclin-dependent kinase inhibitors, such as p27Kip1 and p21Cip1, effectively canceled the accelerated activation of NF-κB, suggesting that oncogenic Ras-induced cell cycle progression is essential for the hyperactivation of NF-κB. Furthermore, we found that Ras (G12V) augmented the transcriptional activation of NF-κB, and this activation required the p38 MAP kinase. We observed that a downstream kinase of p38 MAP kinase, MSK1, was activated by Ras (G12V) and catalyzed the phosphorylation of p65/RelA at Ser-276, which is critical for its transcriptional activation. Significantly, phosphorylation of the p65/RelA subunit at Ser-276 was elevated in patient samples of colorectal cancer harboring oncogenic mutations of the K-Ras gene, and the expression levels of NF-κB target genes were drastically enhanced in several cancer tissues. These observations strongly suggest that oncogenic signal-induced acceleration of NF-κB activation is caused by activation of the p38 MAP kinase–MSK1 signaling axis and by cell cycle progression in cancer cells.

AB - It is well established that nuclear factor κB (NF-κB) acts as one of the most important transcription factors for tumor initiation and progression, as it both protects cells from apoptotic/necrotic signals and accelerates angiogenesis and tumor metastasis, which is mediated via the expression of target genes. However, it has not yet been clarified how oncogenic signals accelerate the activation of NF-κB. In the current study, we utilized untransformed NIH-3T3 cells stably harboring a κB-driven luciferase gene to show that an oncogenic mutant of Ras GTPase augmented TNFα-induced NF-κB activation. Notably, enforced expression of cyclin-dependent kinase inhibitors, such as p27Kip1 and p21Cip1, effectively canceled the accelerated activation of NF-κB, suggesting that oncogenic Ras-induced cell cycle progression is essential for the hyperactivation of NF-κB. Furthermore, we found that Ras (G12V) augmented the transcriptional activation of NF-κB, and this activation required the p38 MAP kinase. We observed that a downstream kinase of p38 MAP kinase, MSK1, was activated by Ras (G12V) and catalyzed the phosphorylation of p65/RelA at Ser-276, which is critical for its transcriptional activation. Significantly, phosphorylation of the p65/RelA subunit at Ser-276 was elevated in patient samples of colorectal cancer harboring oncogenic mutations of the K-Ras gene, and the expression levels of NF-κB target genes were drastically enhanced in several cancer tissues. These observations strongly suggest that oncogenic signal-induced acceleration of NF-κB activation is caused by activation of the p38 MAP kinase–MSK1 signaling axis and by cell cycle progression in cancer cells.

KW - colorectal cancer

KW - MSK1/2

KW - NF-κB

KW - p65/RelA

KW - Ras

UR - http://www.scopus.com/inward/record.url?scp=85074235233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074235233&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12580

DO - 10.1002/1878-0261.12580

M3 - Article

C2 - 31580526

AN - SCOPUS:85074235233

VL - 13

SP - 2493

EP - 2510

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 11

ER -